SAVE REQUEST

USER: (erj)
FOLDER: K003492 - 6 pages
COMPANY: CAMBRIDGE HEART, INC. (CAMBHEAR)
PRODUCT: COMPUTER, DIAGNOSTIC, PROGRAMMABLE (DQK)
SUMMARY: Product: ANALYTIC SPECTRAL METHOD OF ALTERNANS PROCESSING; CH 2000 CARDIAC DIAG

DATE REQUESTED: Jan 12, 2015
DATE PRINTED: Jan 12, 2015

Note: Printed
510(k) Summary

January 11, 2000

Submitter: Cambridge Heart, Inc
1 Oak Park
Bedford, Ma 01730
(781) 271-1200
(781) 275-8431
Contact: Jeffrey Arnold

510(k) Numbers and Product Codes of equivalent devices:

Cambridge Heart, Inc.; Heartwave (APS) Alternans Processing System
510(k) Number: #K001034
Product Code: 74 DPS
CFR Section: 870.2340

Cambridge heart, Inc.; Model CH 2000 Cardiac Diagnostic System
510(k) Number: #K983102
Product Code: 74 DPS
CFR Section: 870.2340

Indications for Use and Intended Population

The Alternans Processing System used with Analytic Spectral Method of Alternans Processing is intended for the measurement of Microvolt T-Wave Alternans* at rest and during ECG stress testing.

The presence of Microvolt T-wave Alternans as measured by Analytic Spectral Method of Alternans Processing in patients with known, suspected or at risk of ventricular tachyarrhythmia predicts increased risk of a cardiac event (ventricular tachyarrhythmia or sudden death).

The Analytic Spectral Method of Alternans Processing should be used only as an adjunct to clinical history and the results of other non-invasive and/or invasive tests.

The predictive value of T-wave Alternans for cardiac events has not been established in patients with active, untreated ischemia.

*Microvolt T-wave Alternans is defined as T-wave alternans which (a) is measured from high-resolution multi-segment sensors, (b) is present in leads X, Y, Z, VM or two adjacent precordial leads, (c) is at the level of 1.9 microvolts after signal optimization and subtraction of the background noise level, (d) is at least three standard deviations greater than the background noise level, (e) is present at rest or has an onset heart rate.
of below 110 beats per minute, and (f) is sustained at heart rates above the onset heart rate.

Device Description

The Cambridge Heart Alternans Processing System is intended for use with computer-based ECG systems which include the feature for the measurement and recording of T-Wave alternans. The alternans levels reported in K983102 were measured using the Analytic Spectral Method. This method consists of several computational steps that combine to form a unique analytical process. The Microvolt T-wave Alternans measurement, the output of this specific process, has been shown to be useful in predicting ventricular tachyarrhythmias and sudden cardiac death. The analytical process is embodied in software and incorporated into a device for the measurement of T-Wave alternans, designed for use in conjunction with a host adapter/controller for ECG functions. The host may be any ECG recording or stress test system. In the case of the Model CH 2000 Cardiac Diagnostic System the host controller is an integral part of the device (K983102).

The Cambridge Heart Alternans processing System using the Analytic Spectral Method of Alternans Processing adds T-wave alternans diagnostic capabilities to standard stress test systems and ECG recording devices. The Alternans processing System using the Analytic Spectral Method of Alternans Processing is intended for the measurement of microvolt T-Wave alternans at rest and during treadmill, ergometer and pharmacologic stress testing.

The Alternans Processing System works in conjunction with a host standard-stress ECG controller. In the Cambridge Heart Model CH 2000 Cardiac Diagnostic System, the host controller is integral to the device (K983102). Attachment to the patient is through the Cambridge Heart patient module(s). Digitized signals from the patient module are used as inputs to the Analytic Spectral Method for Alternans processing.

The Alternans test using the Alternans Processing System is performed with seven standard stress test electrodes and seven proprietary multi-segment Micro-V Alternans Sensors. The electrodes and sensors are attached through a leadwire set to the belt-worn Patient module, which provides digitized data to the Alternans Processor.

Patient Electrodes: Patient electrodes designed and approved specifically for use during exercise stress testing should be used at all times with the Alternans Processing System.

Measurement of alternating beat to beat T-wave amplitude (alternans) requires the use of the Cambridge Heart Hi-Res Electrode (Ref: # K962115) or The Cambridge Heart Micro-V Alternans Sensor (Ref: #K002230) in conjunction with other Patient electrodes designed and approved specifically for use during exercise stress testing.
Performance Standards

The Alternans Processing System using the Analytic Spectral Method of Alternans Processing integrated with the Cambridge Heart HeartWave™ Alternans Processing System or the Cambridge Heart Model CH 2000 Cardiac Diagnostic System meet the following Performance Standards:

ANSI/AAMI EC11-1991


EN60601-1-1: 1993, "Medical Electrical Equipment, Part 1: General Requirements for Safety - Section 1.1 Collateral standard: Safety requirements for medical electrical systems"


Conclusion

There are more similarities than differences between the predicate device(s) and the Alternans Processing System. Both the predicate devices use the Analytic Spectral Method of Alternans Processing. When used in accordance with the directions for use, by qualified personnel, the Alternans Processing System is safe and effective, as indicated, for its intended use.
Cambridge Heart, Inc.
c/o Mr. John Greenbaum
Generic Devices Consulting
20310 SW 48th Street
Fl. Lauderdale, FL 33332

Re: K003492
Cambridge Heart Alternans Processing System
Regulatory Class: II (two)
Product Code: 74 DQK
Dated: November 9, 2000
Received: November 13, 2000

Dear Mr. Greenbaum:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

[Signature]

James E. Dillard III
Director
Division of Cardiovascular and Respiratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Device Name: Alternans Processing System

Indications For Use:

The Alternans Processing System used with the Analytic Spectral Method of Alternans processing is intended for the measurement of Microvolt T-Wave Alternans* at rest and during ECG stress testing.

The presence of Microvolt T-wave Alternans as measured by the Analytic Spectral Method of Alternans Processing in patients with known, suspected or at risk of ventricular tachyarrhythmia predicts increased risk of a cardiac event (ventricular tachyarrhythmia or sudden death).

The Analytic Spectral Method of Alternans Processing should be used only as an adjunct to clinical history and the results of other non-invasive and/or invasive tests.

The predictive value of T-wave Alternans for cardiac events has not been established in patients with active, untreated ischemia.

*Microvolt T-wave Alternans is defined as T-wave alternans which (a) is measured from high-resolution multi-segment sensors, (b) is present in leads X, Y, Z, VM or two adjacent precordial leads, (c) is at the level of 1.9 microvolts after signal optimization and subtraction of the background noise level, (d) is at least three standard deviations greater than the background noise level, (e) is present at rest or has an onset heart rate of below 110 beats per minute, and (f) is sustained at heart rates above the onset heart rate.

Concurrence of CDRH, Office of Device Evaluation (ODE)